Medical morbidity and mortality in schizophrenia: Guidelines for psychiatrists

被引:231
作者
Goff, DC
Cather, C
Evins, AE
Henderson, DC
Freudenreich, O
Copeland, PM
Bierer, M
Duckworth, K
Sacks, FM
机构
[1] Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Endocrinol Program, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Hlth Care Homeless Program, Boston, MA 02114 USA
[4] Massachussets Dept Mental Hlth, Boston, MA USA
[5] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
D O I
10.4088/JCP.v66n0205
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Medical morbidity and mortality rates remain elevated in schizophrenia patients compared with the general population, in part due to potentially reversible medical risk factors. Psychiatrists should address this problem by adopting established strategies for prevention and intervention. Method: The literature on modifiable medical risk factors relevant to individuals with schizophrenia and corresponding guidelines for prevention and treatment established by expert consensus panels were reviewed. Results: Schizophrenia patients are at elevated risk for cardiovascular disease due to high rates of cigarette smoking and, increasingly, due to obesity, diabetes, and hypertriglyceridemia. Rates of human immunodeficiency virus infection and infectious hepatitis are also higher in schizophrenia patients. Interventions that have reduced medical morbidity in the general population can be adopted to reduce premature mortality in individuals with schizophrenia. Conclusions: Patients with schizophrenia have high rates of potentially reversible medical morbidity. Implementation of practice guidelines for identifying and modifying risk factors could substantially improve the health of patients with schizophrenia.
引用
收藏
页码:183 / 194
页数:12
相关论文
共 127 条
[71]   Changes in body mass index for individuals with and without schizophrenia, 1987-1996 [J].
Homel, P ;
Casey, D ;
Allison, DB .
SCHIZOPHRENIA RESEARCH, 2002, 55 (03) :277-284
[72]  
HUGHES JR, 1986, AM J PSYCHIAT, V143, P993
[73]  
Iademarco Michael F, 2003, Semin Respir Infect, V18, P225
[74]  
Jin Hua, 2002, Ann Clin Psychiatry, V14, P59, DOI 10.1023/A:1015228112495
[75]  
KALICHMAN SC, 1994, AM J PSYCHIAT, V151, P221
[76]  
KALICHMAN SC, 1995, PSYCHIATR SERV, V46, P275
[77]  
KASSLER WJ, 1992, PRIMARY CARE, V19, P19
[78]  
Katz RC, 1996, AIDS EDUC PREV, V8, P457
[79]   Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia [J].
Kinon, BJ ;
Basson, BR ;
Gilmore, JA ;
Tollefson, GD .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (02) :92-100
[80]  
Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512